386 related articles for article (PubMed ID: 11443583)
1. Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight.
Neal DA; Gimson AE; Gibbs P; Alexander GJ
Liver Transpl; 2001 Jun; 7(6):533-9. PubMed ID: 11443583
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients.
Manzarbeitia C; Reich DJ; Rothstein KD; Braitman LE; Levin S; Munoz SJ
Liver Transpl; 2001 Feb; 7(2):93-9. PubMed ID: 11172391
[TBL] [Abstract][Full Text] [Related]
3. Serum cholesterol changes in long-term survivors of liver transplantation: a comparison between cyclosporine and tacrolimus therapy.
Charco R; Cantarell C; Vargas V; Capdevila L; Lázaro JL; Hidalgo E; Murio E; Margarit C
Liver Transpl Surg; 1999 May; 5(3):204-8. PubMed ID: 10226111
[TBL] [Abstract][Full Text] [Related]
4. Improved attainment of NKF classified lipid target levels after conversion from cyclosporine to tacrolimus in renal graft recipients.
Pohanka E; Margreiter R; Sparacino V; Sperschneider H;
Transplant Proc; 2005 May; 37(4):1874-6. PubMed ID: 15919490
[TBL] [Abstract][Full Text] [Related]
5. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion.
White M; Haddad H; Leblanc MH; Giannetti N; Pflugfelder P; Davies R; Isaac D; Burton J; Chan M; Azevedo E; Howlett J; Ignaszewski A; Busque S; Cantarovich M; Ferguson R; Genest J; Ross H
J Heart Lung Transplant; 2005 Jul; 24(7):798-809. PubMed ID: 15982605
[TBL] [Abstract][Full Text] [Related]
6. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
8. Impact of changing immunosuppressive monotherapy from Cyclosporin A to Tacrolimus in long-term, stable liver transplant recipients.
Ott R; Bussenius-Kammerer M; Reck T; Koch CA; Kissler H; Hohenberger W; Müller V
Transpl Int; 2004 Jan; 17(1):39-43. PubMed ID: 14504723
[TBL] [Abstract][Full Text] [Related]
9. The impact on biochemical profiles and allograft function for patients converted from cyclosporine to tacrolimus after clinical heart transplantation.
Wang CH; Chou NK; Ko WJ; Chi NH; Tsao CI; Wang SS
Transplant Proc; 2008 Oct; 40(8):2600-2. PubMed ID: 18929812
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
11. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus as intervention in the treatment of hyperlipidemia after liver transplant.
Roy A; Kneteman N; Lilly L; Marotta P; Peltekian K; Scudamore C; Tchervenkov J
Transplantation; 2006 Aug; 82(4):494-500. PubMed ID: 16926593
[TBL] [Abstract][Full Text] [Related]
13. Effects of cyclosporine-tacrolimus switching in posttransplantation hyperlipidemia on high-density lipoprotein 2/3, lipoprotein a1/b, and other lipid parameters.
Seymen P; Yildiz M; Türkmen MF; Titiz MI; Seymen HO
Transplant Proc; 2009 Dec; 41(10):4181-3. PubMed ID: 20005364
[TBL] [Abstract][Full Text] [Related]
14. Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients.
Beckebaum S; Klein C; Varghese J; Sotiropoulos GC; Saner F; Schmitz K; Gerken G; Paul A; Cicinnati VR
Aliment Pharmacol Ther; 2009 Oct; 30(8):834-42. PubMed ID: 19624550
[TBL] [Abstract][Full Text] [Related]
15. Do blood pressure and arterial wall properties change after conversion from cyclosporine to tacrolimus?
Gelens MA; Christiaans MH; v Hooff JP
Transplant Proc; 2005 May; 37(4):1900-1. PubMed ID: 15919498
[TBL] [Abstract][Full Text] [Related]
16. Adult liver transplantation and steroid-azathioprine withdrawal in cyclosporine (Sandimmun)-based immunosuppression - 5 year results of a prospective study.
Lerut JP; Ciccarelli O; Mauel E; Gheerardhyn R; Talpe S; Sempoux C; Laterre PF; Roggen FM; Van Leeuw V; Otte JB; Gianello P
Transpl Int; 2001 Dec; 14(6):420-8. PubMed ID: 11793040
[TBL] [Abstract][Full Text] [Related]
17. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
[TBL] [Abstract][Full Text] [Related]
18. Regression of new-onset diabetes mellitus after conversion from tacrolimus to cyclosporine in liver transplant patients: results of a pilot study.
Lorho R; Hardwigsen J; Dumortier J; Pageaux GP; Durand F; Bizollon T; Blanc AS; Di Giambattista F; Duvoux C
Clin Res Hepatol Gastroenterol; 2011 Jun; 35(6-7):482-8. PubMed ID: 21530445
[TBL] [Abstract][Full Text] [Related]
19. Conversion from tacrolimus to cyclosporine could improve control of posttransplant diabetes mellitus after renal transplantation.
Ramos-Cebrián M; Torregrosa JV; Gutiérrez-Dalmau A; Oppenheimer F; Campistol JM
Transplant Proc; 2007 Sep; 39(7):2251-3. PubMed ID: 17889154
[TBL] [Abstract][Full Text] [Related]
20. Blood pressure profile and treatment quality in liver allograft recipients-benefit of tacrolimus versus cyclosporine.
Dikow R; Degenhard M; Kraus T; Sauer P; Schemmer P; Uhl W; Büchler M; Zeier M
Transplant Proc; 2004 Jun; 36(5):1512-5. PubMed ID: 15251373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
